Introduction
Mdm2 protein is commonly overexpressed in hematologic malignancies due to increased transcription or translation rather than amplification (Capoulade et al., 1998) . As many as half of all human and murine lymphomas overexpress Mdm2 protein, including lymphomas that have inactivated the tumor suppressor p53 or p14/p19 ARF (Watanabe et al., 1996; Eischen et al., 1999; Alt et al., 2003; Wilda et al., 2004; Ghobrial et al., 2005) . Mdm2 is an essential intermediary in the ARFp53 tumor suppressor pathway. As an E3 ubiquitin ligase, Mdm2 transfers ubiquitin to p53, targeting it for degradation (Honda et al., 1997) . Mdm2 can also block the transactivation functions of p53 (Momand et al., 1992) . Mdm2 is regulated, in part, by ARF, which can inhibit Mdm2 from targeting p53 . As a transcriptional target of p53, Mdm2 has control over its own expression (Barak et al., 1993; Wu et al., 1993) . Mdm2 is upregulated in response to stimuli that activate p53, including g-irradiation, hyperproliferative signals and hypoxia (Levine et al., 2006) . This feedback control of p53 by Mdm2 keeps p53 in check.
The role of Mdm2 and the ARF-p53 pathway in B-cell lymphoma development has been studied using the Em-myc transgenic mouse model. Em-myc transgenic mice overexpress the oncogene c-Myc in B cells and consequently develop non-Hodgkin's B-cell lymphoma (Adams et al., 1985) . Overexpression of c-Myc in B cells results in the activation of the ARF-Mdm2-p53 tumor suppressor pathway, which leads to apoptosis (Eischen et al., 1999) . Generation of DNA breaks, which activates p53, is also a consequence of c-Myc overexpression (Vafa et al., 2002) . Not surprisingly, inactivation of p53 or ARF occurs in half of the B-cell lymphomas arising in Em-myc transgenic mice (Eischen et al., 1999) . Moreover, loss of one allele of Mdm2 profoundly suppressed B-cell lymphoma development due to increased p53-dependent B-cell apoptosis (Alt et al., 2003; Eischen et al., 2004) . Curiously, Mdm2 overexpression was frequently observed in B-cell lymphomas in Em-myc transgenic mice irrespective of p53 or ARF expression, including lymphomas that only had one allele of Mdm2 (Eischen et al., 1999 (Eischen et al., , 2004 Alt et al., 2003) . Moreover, Mdm2 transgenic mice, in which Mdm2 is under transcriptional control of its native promoter, develop lymphomas, the cellular origin of which were not determined, or sarcomas late in life (Jones et al., 1998) . Therefore, Mdm2 overexpression appears to have an important role in lymphomagenesis. Yet, little is known about the cellular processes that are influenced by Mdm2 overexpression in B cells in vivo that contribute to B-cell lymphoma development.
Here, we took advantage of Mdm2 transgenic mice demonstrating the critical biological processes that are corrupted due to Mdm2 overexpression that lead to B-cell transformation. We also show that Mdm2 overexpression cooperates with Myc in the development of B-cell lymphoma. The data suggest the enhancement of lymphomagenesis is due to the increased proliferation and the survival advantage conferred to B cells by overexpression of Mdm2, but also due to increased chromosomal instability in the B cells that expressed elevated levels of Mdm2. Therefore, we provide direct evidence showing Mdm2 overexpression impacts multiple cellular processes that when altered facilitate B-cell transformation, establishing Mdm2 as a key contributor to B-cell lymphomagenesis and an explanation for why upregulation of Mdm2 is frequently observed in lymphoma.
Results

Increased Mdm2 expression in B cells from Mdm2 transgenic mice
To determine the role Mdm2 has in B-cell lymphoma development, we first identified a mouse model that overexpressed Mdm2 in B cells. Mdm2 transgenic mice where Mdm2 is regulated by its native promoter were previously generated (Jones et al., 1998) . These mice were shown by northern blot to have a 3-4-fold increased expression of Mdm2 RNA in their spleens, an organ where the majority of B cells reside. To confirm this result, we performed quantitative real-time (qRT) PCR on splenocytes. There were low steady-state levels of Mdm2 mRNA in spleens from both Mdm2 transgenics and non-transgenic littermates. As expected, spleens from Mdm2 transgenics showed a 2.3-5.4-fold increase in Mdm2 mRNA levels over controls (Figure 1a ).
Developing B cells in Mdm2 transgenics also overexpressed Mdm2. Bone marrow-derived pre-B cells from Mdm2 transgenic mice expressed a 2.9-4.3-fold increase in Mdm2 mRNA over that of the levels expressed in non-transgenic littermates (Figure 1b) . Moreover, the elevated expression of Mdm2 mRNA in both mature and precursor B cells from Mdm2 transgenics was enhanced compared to controls following g-irradiation ( Supplementary Figures S1A and B) .
Increased Mdm2 transcription led to elevated Mdm2 protein expression in B cells in Mdm2 transgenic mice. Both steady-state and g-irradiation-induced Mdm2 protein levels were higher (2-3-fold) in spleens from Mdm2 transgenics as compared to non-transgenic littermates (Figure 2a) . The increased levels of Mdm2 protein resulted in decreased levels of p53 protein in the Mdm2 transgenics. The difference in the levels of total p53 protein between the two genotypes was reflected in the amount of activated p53 (Canman et al., 1998) . There were lower levels of phosphorylated serine 18 of p53 (activated p53) in Mdm2 transgenic spleens post irradiation as compared to controls (Figure 2a) . A Mdm2 transgenic (Tg þ ) or non-transgenic littermate controls (TgÀ) were left unirradiated (À) or were subjected to g-irradiation (IR, þ ). (a) Equal concentrations of whole cell lysates from splenocytes were western blotted with antibodies specific for the proteins labeled to the left of the panels. Phos-p53 is phosphorylated serine 18 of p53. (b) p21 mRNA levels in each spleen were determined by qRT-PCR after normalizing each sample to b-actin mRNA levels. Each bar is a mean of triplicate samples with error bars equal to one standard deviation.
Mdm2 facilitates lymphoma development P Wang et al consequence of reduced levels of activated p53 is decreased p53-dependent transcription of genes necessary to respond to the irradiation, such as p21. Mdm2 transgenic spleens had less p21 mRNA in the absence of g-irradiation, and following irradiation, the induction of p21 was significantly blunted (Figure 2b ). Reduced p21 transcription resulted in decreased p21 protein levels (Figure 2a) . Therefore, Mdm2 protein is increased in splenocytes in Mdm2 transgenic mice and this results in suppression of p53 activation in vivo.
Mdm2 overexpression conferred a growth and survival advantage to B cells To assess the biological consequences of elevated Mdm2 expression in B cells, we measured B-cell growth and proliferation. An equal number of Mdm2 transgenic and littermate control bone marrow-derived pre-B cells were placed in culture. Within five days there were increased numbers of viable Mdm2 transgenic pre-B cells as compared to non-transgenic controls (Figure 3a ). To determine whether the elevated cell number was due to an increase in proliferation and/or a decrease in apoptosis, we evaluated both. There was increased incorporation of 3 H-thymidine and bromodeoxyuridine (BrdU) in cultures of pre-B cells from Mdm2 transgenics, as compared to the control pre-B cells ( Figures  3b and c) , indicating an increased rate of proliferation. Since p53 regulates the expression of genes whose function is to inhibit cell cycle progression, such as p21, we investigated levels of p21. In two sets of littermates, steady-state p21 mRNA levels were decreased in pre-B cells from Mdm2 transgenic mice as compared to non-transgenics (Figure 3d ), which provides an explanation for the differences in proliferation. Analysis of steady-state rates of apoptosis and viability showed no detectable difference between the Mdm2 transgenic pre-B cells and controls (data not shown). Moreover, no difference in the rate of apoptosis induced by IL-7 cytokine deprivation, a p53-independent process, was observed between the two genotypes ( Figure 4a ). These results indicate that elevated Mdm2 expression increases B-cell proliferation but does not alter B-cell susceptibility to spontaneous apoptosis or apoptosis induced by growth factor deprivation.
To determine whether susceptibility to apoptotic stimuli of the Mdm2 overexpressing pre-B cells also extended to p53-dependent apoptosis, we measured their response to g-irradiation and oncogene overexpression. Mdm2 transgenic pre-B cells had increased viability at all intervals measured following low dose (2 Gy) g-radiation or activation of Myc with 4-hydroxytomoxifen (4-HT) in MycER expressing pre-B cells (Figures 4b  and c) . Moreover, the Mdm2 transgenic pre-B cells recovered more quickly from the irradiation and began proliferating, which accounted for the difference in cell numbers between the two genotypes at 72 h postirradiation. At higher doses of g-irradiation (5-10 Gy), the response of which is in part p53 independent, there was no significant difference in pre-B-cell survival between the two genotypes (data not shown). Mdm2 transgenic pre-B cells did succumb to Myc-induced apoptosis, but it was protracted as compared to the nontransgenics. These data indicate that elevated Mdm2 expression in pre-B cells suppresses the p53 response, resulting in inhibition of p53-dependent apoptosis and increased survival.
Mdm2 overexpression increased B-cell genomic instability
We postulated that if B cells proliferated more rapidly, had an increased resistance to p53-mediated apoptosis, and were able to suppress p53 activation, then they should be more susceptible to the development of chromosomal aberrations. A total of 637 individual metaphases from three separate Mdm2 transgenic pre-Bcell cultures each with a littermate control were evaluated for chromosomal abnormalities. Mdm2 transgenic pre-B cells had a significantly greater number of Mdm2 facilitates lymphoma development P Wang et al cells that were aneuploid (less than or greater than 40 chromosomes) as compared to non-transgenic controls ( Figure 5a ). Loss of one or more chromosomes was more frequent than gain of one or more chromosomes (Figure 5b ). Tetraploid Mdm2 transgenic pre-B cells were extremely rare. Other chromosomal abnormalities such as breaks or fusions were not observed in pre-B cells.
To determine whether mature B cells exhibited a similar increase in chromosomal instability, metaphases from splenocytes (448 total) and purified splenic B cells (540 total) were analysed. There was significantly increased aneuploidy in splenocytes in three out of five Mdm2 transgenics; however, as a group, their difference to non-transgenics did not reach statistical significance (P ¼ 0.19; Figure 5c ). In contrast, there was a significantly greater percentage of metaphases with chromosomal/chromatid breaks in splenocytes from Mdm2 transgenics as compared to controls (P ¼ 0.005; Figure 5d ). Moreover, there was an increased frequency of metaphases from Mdm2 transgenics that had breaks and were also aneuploid as compared to non-transgenics (1.2 vs 0%, respectively). Examples of metaphases from splenocytes are shown in Supplementary Information (Supplementary Figures S2A-H) . Analysis of metaphases from purified mature splenic B cells from four littermates showed similar results. There was a significantly increased frequency of chromosomal alterations, including aneuploidy and chromosomal/chromatid breaks, in mature B cells from Mdm2 transgenics, as compared to non-transgenic littermates (P ¼ 0.003 and 0.009, respectively) (Figures 5e and f). Tetraploid metaphases, chromosomal fusions, exchanges and other chromosomal abnormalities were exceedingly rare and not statistically significant, but observed only in Mdm2 transgenics (data not shown). Although both developing and mature B cells showed signs of chromosomal instability when Mdm2 was overexpressed, evaluation of B-cell populations in the bone marrow and spleens of Mdm2 transgenic mice revealed that B-cell development appeared normal. Similar numbers of pro-B, pre-B, immature B and mature B cells were present in Mdm2 transgenics and non-transgenic littermates (data not shown). Therefore, elevated Mdm2 expression increased chromosomal instability, but did not appear to alter B-cell maturation in vivo.
Mdm2 overexpression can lead to lymphoma
To determine whether the alterations in proliferation, apoptosis and chromosomal stability in Mdm2 transgenic mice lead to B-cell lymphomas, we evaluated tumors that developed in a cohort of Mdm2 transgenics for lymphoma. Half (12 of 25) of the Mdm2 transgenic mice developed lymphoma, a similar frequency as previously reported (14 of 26, Jones et al., 1998) . Lymphoma cells were evident in the spleen, lymph nodes, liver and occasionally in the kidneys and lungs of the Mdm2 transgenic mice, and most were of large cell type (Figures 6a and d) . Immunohistochemistry and flow cytometry revealed that three of the lymphomas stained positive for T-cell markers and negative for B-cell markers, and one lymphoma appeared to be composed of primarily myeloid cells and was negative for both B-and T-cell markers. Interestingly, 8 out of 12 of the lymphomas were of mixed cell origin and had both B-and T-cell components. The proportion of lymphoma cells that was positive for B-cell markers (B220 and IgM) and T-cell markers (CD3 and CD4) varied between the eight lymphomas. For example, there were lymphomas that appeared to have equal numbers of B and T cells (Figures 6a-c) , whereas other lymphomas had a greater number of B cells (Figures 6d-f ) Mdm2 facilitates lymphoma development P Wang et al or more T cells (data not shown). These results are indicative of a polymorphic lymphoma that arose from a common precursor cell or a lymphoma that is of mixed lineage, which are rare lymphoma types in this background of mouse. Therefore, 2/3 of the lymphomas arising in Mdm2 transgenic mice expressed B-cell markers, but were not considered strictly a B-cell lymphoma. Nevertheless, the data show that B cells and/or B-cell precursors in Mdm2 transgenic mice can develop into a lymphoma.
Mdm2 overexpression accelerated Myc-initiated B-cell lymphoma development
To determine the consequences of Mdm2 overexpression in a model of B-cell lymphoma, Mdm2 transgenic mice were mated to Em-myc transgenic mice. Em-myc transgenic mice overexpress c-Myc specifically in B cells and consequently spontaneously develop B-cell lymphoma (Adams et al., 1985) . Mdm2/Em-myc double transgenics rapidly developed lymphoma. The lymphomas that emerged were typical pre-B/B-cell lymphomas that are characteristic of Em-myc transgenic mice (data (Figure 7) . Notably, a quarter of the Em-myc single transgenics were still alive at 150 days, whereas none of the double transgenics survived past 112 days (Figure 7) . Therefore, Mdm2 overexpression cooperated with Myc to accelerate B-cell lymphoma development. We also evaluated whether there was cooperation between Mdm2 and Myc on loss of DNA stability prior to lymphoma development. Metaphase spreads were analysed from splenocytes from young (3-4 weeks old) pre-cancerous Em-myc single transgenic and Mdm2/ Em-myc double transgenic mice. Mdm2/Em-myc double transgenic splenocytes consistently had a significantly increased frequency of chromosomal/chromatid breaks and aneuploidy over that of non-transgenic littermates (Figures 5c and d) . However, with the exception of two mice, which had a slightly higher percentage of breaks, splenocytes from Mdm2 single transgenics had a similar percentage of chromosomal/chromatid breaks or aneuploidy as compared to Em-myc single transgenics or Mdm2/Em-myc double transgenics. One Mdm2/Em-myc double transgenic mouse had severe aneuploidy, indicative of an early-stage lymphoma, although no overt lymphoma was detected. Therefore, Mdm2 and Myc overexpression both increased DNA instability, but there was no obvious additive effect on chromosomal instability of overexpressing both proteins.
Inactivation of p53 is an infrequent event in
Mdm2/Em-myc double transgenic lymphomas To determine whether Mdm2 overexpression impacted the genetic alterations selected for during B-cell lymphomagenesis, the status of p53 and ARF in the B-cell lymphomas that emerged in the Mdm2/Em-myc double transgenics were evaluated. Western blots revealed only two lymphomas had high levels of p53 protein together with elevated levels of ARF (Figure 8a ), which is indicative of mutant p53 (Eischen et al., 1999; Alt et al., 2003) . In contrast to Em-myc single transgenics where 25% of the lymphomas that arise have mutated p53, only 7% (2 of 28) of the Mdm2/Em-myc double transgenic lymphomas had mutations in p53. Sequencing revealed point mutations in the DNA binding domain of p53, the most common site of p53 mutations, in 227 and 002 lymphomas. Lymphomas from the other Mdm2/Em-myc double transgenics retained wild-type p53. Deletion of p53, although rare for Em-myc lymphomas that have both copies of p53, was also considered. Darker exposures of p53 western blots showed p53 protein was expressed in all of the Mdm2/ Em-myc double transgenic lymphomas and ARF levels were within normal ranges or not detectable (Figure 8a ), indicating that p53 did not appear to be deleted in any of the lymphomas. Since ARF is frequently deleted in Em-myc lymphomas (24%, Eischen et al., 1999) , and ARF protein is normally expressed at very low levels in vivo and not detected on western blots, as we observed, we performed Southern blots for ARF. The ARF locus was absent in 6 of 28 Mdm2/ Em-myc transgenic lymphomas, indicating there were biallelic ARF deletions in 21% of the lymphomas analysed (Figure 8b ). Therefore, in Mdm2/Em-myc transgenic lymphomas, the frequency of ARF deletions was similar to that of Em-myc single transgenics, but there was a reduction in the number of lymphomas that had inactivated p53. Figure 7 Mdm2 overexpression accelerates Myc-induced lymphoma development. Kaplan-Meier survival curves of Mdm2 single transgenic (Mdm2), Em-myc single transgenic (Myc) and Mdm2/ Em-myc (Mdm2/Myc) double transgenic mice. The genotypes and the numbers (n) of the mice are labeled next to each curve. The average survival time of Em-myc single and Mdm2/Em-myc double transgenic mice was 172 and 58 days, respectively, which was statistically significant (log-rank test, Po0.001). All Em-myc mice developed lymphoma. Mdm2 facilitates lymphoma development P Wang et al
Discussion
Our study focused on the biological processes most closely linked to cellular transformation and how a small increase in Mdm2 protein expression in vivo impacted these processes in B cells. Specifically, we showed that elevated levels of Mdm2 accelerated proliferation, conferred resistance to oncogene-initiated p53-dependent apoptosis, and increased the frequency of genomic instability in primary B cells. The growth and survival advantages, in addition to increasing chromosomal instability, make for perfect conditions for B-cell transformation. A lymphocyte that has reduced ability to inhibit cell cycle progression and undergo apoptosis, as well as spontaneously acquiring chromosomal changes should have an increased potential of developing into a lymphoma, and our data support this concept. This study expands on previous data in limited mouse models on the consequences of Mdm2 overexpression and provides the first in vivo evidence of the effects on B cells of elevated Mdm2 levels. Our results also provide a clear rationale for why Mdm2 overexpression is frequently selected for in human and murine B-cell lymphomas. Our results also imply that targeting Mdm2 in lymphomas with increased Mdm2 expression should be a potent therapeutic approach. In support of this notion, Mdm2 inhibitors have been used on hematologic and non-hematologic malignancies that overexpress Mdm2 inducing apoptosis and blocking cell cycle progression (Vassilev, 2007) . However, caution is warranted since activation of p53 due to decreased Mdm2 expression or other means puts pressure on lymphoma cells to select for p53 mutations or deletions (Alt et al., 2003; Martins et al., 2006) , making them more resistant to therapy.
In previous studies, B cells that have a hyperproliferative signal, such as c-Myc overexpression, undergo apoptosis. When apoptosis is suppressed through deletion of p53, ARF, or the apoptotic mediator Bax or overexpression of the apoptotic inhibitor Bcl-2, lymphoma rapidly ensues (Strasser et al., 1993; Eischen et al., 1999 Eischen et al., , 2001a . Conversely, reduced expression of Mdm2 increases B-cell apoptosis, which then suppresses B-cell lymphomagenesis (Alt et al., 2003) . However, it has become apparent in recent years that regulation of chromosomal stability is as critical to inhibit transformation as control over cell cycle and apoptosis. Chromosomal/chromatid breaks and aneuploidy are marks of genetic instability, and we observed an increased frequency of both in B cells from Mdm2 transgenic mice. Humans that lack or have reduced ability to fix DNA breaks or damage and maintain normal chromosomes have high incidences of cancer, particularly lymphoma (Digweed and Sperling, 2004; Gumy-Pause et al., 2004) . It is believed that lymphoma frequently develops due to the DNA double-strand breaks and the subsequent errors in ligations that occur during B-and T-cell receptor rearrangements during lymphocyte development (Franco et al., 2006) . Our results are consistent with this idea that increased genomic instability increases the incidence of lymphoma, as evidenced by increased B-cell chromosomal instability and lymphoma development in the Mdm2 transgenic mice.
We determined that Mdm2 overexpression in B cells led to chromosomal and chromatid breaks and loss or gain of one or more chromosomes. Although the exact mechanism of these DNA breaks is still unknown, inhibition of p53 due to increased levels of Mdm2 could lead to DNA instability. However, we have recently determined that overexpression of Mdm2 inhibited DNA double-strand break repair independent of p53 and possibly through its interactions with Nbs1, a component of a DNA repair complex (Alt et al., 2005) . c-Myc overexpression, on the other hand, has been shown to induce DNA double-strand breaks rather than inhibit their repair (Vafa et al., 2002) . In spite of this, we did not detect an additive effect of overexpressing both c-Myc and Mdm2 in precancerous B cells. This finding was somewhat expected, as untransformed B cells should only be able to sustain so much damage to their chromosomes before they cannot tolerate it and die, as evidenced by their sensitivity to g-irradiation. Therefore, our results in B cells indicate that Mdm2 alone can induce chromosomal instability and a greater transformation potential. In support of this idea, loss of one allele of Mdm2 in ARF-null mouse embryo fibroblasts, which are predisposed to transformation, resulted in increased chromosomal stability with fewer breaks, fusions and exchanges and a decreased transformation ability (Wang et al., 2006) . Moreover, Mdm2 overexpression in breast epithelial cell-specific Mdm2 transgenic mice in the presence or absence of p53, led to multinucleated polyploid epithelial cells (Lundgren et al., 1997) . We have observed similar findings to these in fibroblast cells (TL and CME, unpublished data), but rarely have we seen multinucleated hematopoietic cells from overexpressing Mdm2. Less than 1% of all metaphases analysed from Mdm2 transgenic B cells were tetraploid, as most lost or gained one or a few chromosomes and did not duplicate their entire genome. This is in contrast to p53-null cells that rapidly become tetraploid and then develop aneuploidy (Cross et al., 1995) . Therefore, the effects of increased Mdm2 expression on DNA stability and the contribution of p53 to this process need further investigation.
Materials and methods
Mice
Mdm2 transgenics (Jones et al., 1998) were mated to Em-myc transgenic mice (Adams et al., 1985) to generate single and double transgenics and non-transgenic littermate control mice. At signs of disease, tissues/tumors were collected and evaluated as described in the Supplementary Information. Radiation of mice is also described in Supplementary Information. All research with mice complied with all federal and institutional guidelines.
Phenotype analysis
Cells from lymphomas, whole spleens and bone marrow from wild-type, Mdm2 transgenic, Em-myc transgenic and Mdm2/ Em-myc double transgenic mice prior to the development of Mdm2 facilitates lymphoma development P Wang et al lymphoma were analysed by flow cytometry as previously described (Eischen et al., 1999; Alt et al., 2003) .
Primary pre-B cells (retrovirus infection, apoptosis, growth, viability, proliferation) Primary pre-B cells were generated from 5-to 8-week-old Mdm2 transgenic and non-transgenic littermate controls, as previously described (Eischen et al., 1999) . Primary pre-B cells were infected with MSCV-MycER-IRES-GFP or MSCV-IRES-GFP retroviruses and apoptosis was induced, as described previously (Eischen et al., 1999) . Fragmented (sub-G1) DNA was quantified following propidium iodide (PI) staining and flow cytometry. BrdU incorporation was performed as we previously described (Wang et al., 2006) . 3 H-thymidine incorporation was determined daily in triplicate following co-culture with 1 mCi 3 H-thymidine. Pre-B cells were cultured with and without IL-7 in triplicate and counted daily, as previously described (Eischen et al., 2001b) . Equal numbers of pre-B cells were g-irradiated (2 Gy) from a 137 Cs source and viable/non-viable cells were counted at intervals.
Western and Southern blotting
Spleens or B-cell lymphomas were lysed and proteins western blotted, genomic DNA Southern blotted, and RNA sequenced, as described previously (Eischen et al., 1999; Alt et al., 2003; Wang et al., 2006) . Relative protein expression was determined with densitometry.
Quantitative real-time PCR qRT-PCR was performed in triplicate with Mdm2, p21 and b-actin-specific primer pairs. The results are expressed in 2
ÀdeltaCt using b-actin as a reference. Additional details are described in Supplementary Information.
Chromosome stability analysis
Metaphase spreads were prepared and analysed with standard protocols as we previously described (Wang et al., 2006) . Each metaphase was evaluated for chromosomal aberrations. Chromosomal or chromatid breaks had to be observable by both fluorescent DNA stains (PI and DAPI) and have a visible separation (gap) to be counted as a break. The total number of chromosomes in each metaphase was counted twice by hand and/or with computer software from photographs (Image Tool, San Antonio, TX, USA). Additional details are available in Supplementary Information.
